Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

The association between cardiac involvement and long-term clinical outcomes in patients with Duchenne muscular dystrophyopen access

Authors
Cha, Jung-JoonKim, In-SooKim, Jong-YounChoi, Eui-YoungMin, Pil-KiYoon, Young WonLee, Byoung KwonHong, Bum-KeeKwon, Hyuck MoonCho, Han EolChoi, Won AhKang, Seong-WoongRim, Se-Joong
Issue Date
Aug-2022
Publisher
Heart Failure Association of the European Society of Cardiology | Wiley
Keywords
Duchenne muscular dystrophy; LV systolic dysfunction; Long-term clinical outcome; Brain-natriuretic peptide; Diuretics
Citation
ESC Heart Failure, v.9, no.4, pp.2199 - 2206
Indexed
SCIE
SCOPUS
Journal Title
ESC Heart Failure
Volume
9
Number
4
Start Page
2199
End Page
2206
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/60926
DOI
10.1002/ehf2.13970
Abstract
Aims Despite advances in contemporary cardiopulmonary therapies, cardiomyopathy remains the leading cause of death in patients with Duchenne muscular dystrophy (DMD). Also, the long-term clinical outcomes of patients with DMD and cardiomyopathy is unknown. This study investigated long-term clinical outcomes and their associated factors in patients with late-stage DMD. Methods and results A total of 116 patients with late-stage DMD (age > 15 years) were enrolled in this retrospective study. All enrolled patients were followed up at a single tertiary referral hospital. LV systolic dysfunction was dichotomously defined as reduced [left ventricular ejection fraction (LVEF) ≤ 40%] vs. preserved [>40%] based on the initial echocardiographic result. The primary endpoint was all-cause death. The secondary endpoint was a composite event defined as death or unexpected hospitalization due to cardiovascular reasons including chest pain, dyspnoea, and generalized oedema. The patients were divided into preserved (n = 84, 72.4%) and reduced LVEF groups (n = 32, 27.6%). The mean age was 20.8 ± 5.9 years, the mean disease duration, 8.8 ± 3.7 years, and the mean follow-up duration, 1708 ± 659 days. For primary endpoint, the reduced LVEF group showed a lower rate of overall survival (Reduced LVEF vs. Preserved LVEF; 81.3% vs. 98.8%, log-rank P = 0.005). In the multivariable Cox regression analysis, brain-natriuretic peptide (BNP) level (adjusted hazard ratio [HR] 1.088, 95% confidence interval [CI] 1.019–1.162, P = 0.011) and diuretic use (adjusted HR 9.279, 95%CI 1.651–52.148, P = 0.011) were significant predictors of all-cause death in patients with DMD. For the secondary endpoint, the reduced LVEF group had a lower rate of freedom from composite events than the preserved LVEF group (65.6% vs. 86.9%, log-rank P = 0.005). In the multivariable Cox regression analysis, BNP level (adjusted HR 1.057, 95%CI 1.005–1.112, P = 0.032) and diuretic use (adjusted HR 4.189, 95% CI 1.704–10.296, P = 0.002) were significant predictors of the composite event in patients with DMD. Conclusions Patients with DMD and reduced LVEF had worse clinical outcomes than those with preserved LVEF. BNP level and diuretic use were associated with adverse clinical outcomes in patients with late-stage DMD, irrespective of LVEF.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Cardiology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Cha, Jung-Joon photo

Cha, Jung-Joon
안암병원 (Department of Cardiology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE